Cellectricon September newsletter

Can’t see this email properly?

View Online
 
 
 
 
Cellectrion | SIMPLY STIMULATING
 
 
Intro image
 
 

Join us for the IASP World Congress on Pain!

 

Welcome to our September Newsletter where we have a special focus on the ongoing IASP World Congress of Pain which is being held in Boston, MA.

 

This conference poses a great opportunity for sharing the latest developments in the field of pain research. At the meeting, our CSO Paul Karila will together with esteemed collaborators present two posters describing our work on providing the scientific community with the most predictive chronic pain in vitro models possible. 


In other news, we are pleased to welcome Dr. Annika Malmberg to our advisory board. Annika is an experienced neurobiologist and pharmacology expert with a strong pharma background and will support our business development team.


Please do not hesitate to stop by the posters or reach out to arrange a meeting while in Boston!

 
 
 
 

News:

 
 
Image Annika Malmberg
 
 

Dr. Annika Malmberg joins Cellectricon's Strategic Advisory Board

 

With more than 20 years experience from working with drug discovery and development at both biotechs and pharmaceutical companies, Dr. Malmberg will play an important role in supporting Cellectricon’s commercial strategy development.

 

Learn More

 
 
 
 

Poster presentations at IASP WCP:

 
 
 
 

Examination of the Role of Nav1.7 and Nav1.8 in the Generation of Action Potentials both In Vivo and In Vitro

 

In collobration with the Department of Neuroscience, Genentech

 

Poster number: PTH114
Presentation time: Thursday, September 13, 9:30 – 10:30 AM

 

Poster info

 
 
 
 

Disease Relevance In Vitro? Comparison of Excitability in DRG Neurons from Neuropathic and Inflammatory Disease Models

 

In collaboration with the Department of Physiology and Pharmacology, Karolinska Institutet


Poster number: PTH241
Presentation time: Thursday, September 13, 3:15 – 4:15 PM

 

Poster info

 
 
Cellectricon Discovery Services
 
 

Functional and morphological screening in neurons

 

At Cellectricon we have a particular focus on diseases where neuronal excitability and synaptic function matters, such as chronic pain, epilepsy, Alzheimer’s disease and schizophrenia. With our discovery platform, we can create model systems for registering changes in neural activity, both at the cellular and network level.


The heart of our discovery platform is our proprietary Cellaxess® Elektra technology, a revolutionary automated platform for functional screening in living neurons. The system combines localized electric field manipulation with high speed fluorescence imaging to monitor parameters such as neuronal excitability, synaptic efficacy and synaptic plasticity in primary and stem cell-derived neurons. Cellaxess® Elektra is the only system enabling high quality phenotypic assays for compound characterization and target validation in a high-throughput format for these parameters

 

Learn more

 
 
 
 

Upcoming events:

 
 

4-5

October

 

4th Annual Neuroscience R&D Technologies conference

 

Munich, Germany

Don't miss the presentation by Dr. Paul Karila titled:
"Novel approaches and concepts for development of functional in vitro assays targeting neurodegenerative disease discovery"

 

More

 
 
 
in
 
 
 
 
 
Cellectricon AB, Flöjelbergsgatan 8C, SE-431 37 Mölndal, Sweden, Org. No: 556602-0896
Phone: +46 (0)31 760 35 00    E-mail: info@cellectricon.com
This email has been sent to [email address suppressed] as a subscriber to Cellectricon AB.
If you no longer wish to receive these emails, please unsubscribe .